RxDoctor Payments Data

Victor Mejia, MD

Cardiovascular Disease · Trumbull, CTNPI 1245228956

Payments from drug & device makers

$1,806in general payments, 2019–2025

Across 15 payments — averaging $120.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baylis Medical Company Inc$1K
  • Amgen$275
  • Medtronic$193
  • Boston Scientific$180
  • Johnson & Johnson$40
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$72440%
  • Education$1,08260%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,806 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$145,723
Medicare patients
577
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$92,325
EntrestoSacubitril/Valsartan42$52,409
XareltoRivaroxaban23$29,459
Praluent PenAlirocumab12$9,056
Atorvastatin Calcium247$2,036
Rosuvastatin Calcium124$1,657
Metoprolol Succinate104$1,076
Valsartan42$888
Carvedilol97$838
Nebivolol Hcl13$758
ClopidogrelClopidogrel Bisulfate63$721
Ezetimibe38$704
Chlorthalidone27$625
Lisinopril99$621
Midodrine Hcl12$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$40$29,45923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →